1. Home
  2. GOSS vs IPHA Comparison

GOSS vs IPHA Comparison

Compare GOSS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$0.37

Market Cap

101.2M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.26

Market Cap

119.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
IPHA
Founded
2015
1999
Country
United States
France
Employees
N/A
174
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.2M
119.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
GOSS
IPHA
Price
$0.37
$1.26
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$4.19
$5.75
AVG Volume (30 Days)
12.3M
17.8K
Earning Date
05-14-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,471,000.00
N/A
Revenue This Year
N/A
$181.17
Revenue Next Year
$147.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$1.18
52 Week High
$3.87
$2.63

Technical Indicators

Market Signals
Indicator
GOSS
IPHA
Relative Strength Index (RSI) 28.37 43.89
Support Level $0.33 $1.18
Resistance Level $0.60 $1.88
Average True Range (ATR) 0.04 0.08
MACD 0.06 0.01
Stochastic Oscillator 30.41 50.00

Price Performance

Historical Comparison
GOSS
IPHA

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: